ms and semaglutide Q&A 111: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) Pharmacokinetics and weight loss effects

Even in a homogeneous and equal society such as Denmark, obesity is twice as prevalent in socioeconomically disadvantaged groups compared with among people with high income

Perhaps surprisingly, given the inflammatory pathways discussed above, the researchers also found a heightened risk of arthritic disorders in patients using GLP-1 drugs, compared to usual treatment

Chronic administration study Finally, to determine whether exendin-phe1 beta cell effects persist with chronic administration, we administered agonists continuously to HFHS-fed mice for 2 weeks via subcutaneous minipumps, using a relatively low dose of agonist (0.24 nmol kg 1 day 1 ) to reduce the weight-dependent effects

These medications, which mimic the bodys own GLP-1 hormones to regulate appetite and blood sugar, are providing a powerful tool for achieving significant, sustained weight loss